Stock listing
Frankfurt:940 Euroapi SA Aktie
German listing (Frankfurt) of Euroapi SA · home listing Euronext:EAPI
Follow Euroapi SA into a list and get an email when it puts out news.
Share price · FWB:940
€0.645 EUR -0.037 (-5.4%)
Close on Nov 20, 2026
- Day range
- €0.645 – €0.645 EURNov 20, 2026
- Market cap
- €61.62M EURAt the close on Nov 20, 2026 · price × 95.53M shares outstanding
- 52-week range
- €0.645 – €3.210 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €1,995 EURMedian day 21 shares · 9 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:EAPI · Home | €0.642 EUR | -0.057 (-8.2%) | 226,839 | €0.680 | €0.680 | €0.629 | €0.699 | Close on Nov 20, 2026 |
| Frankfurt:940 | €0.645 EUR | -0.037 (-5.4%) | — | €0.645 | €0.645 | €0.645 | €0.682 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:940 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.773 | -0.023 | -2.9% | €0.773 | €0.773 | €0.773 | 256 | |
| €0.796 | -0.008 | -1.0% | €0.820 | €0.827 | €0.794 | 6,836 | |
| €0.804 | -0.009 | -1.1% | €0.804 | €0.804 | €0.804 | 36 | |
| €0.813 | -0.008 | -1.0% | €0.813 | €0.813 | €0.813 | 3 | |
| €0.821 | +0.005 | +0.6% | €0.821 | €0.821 | €0.819 | 13 | |
| €0.816 | +0.008 | +1.0% | €0.803 | €0.819 | €0.800 | 4 | |
| €0.808 | +0.011 | +1.4% | €0.808 | €0.808 | €0.808 | 9,874 | |
| €0.797 | 0.000 | 0.0% | €0.799 | €0.807 | €0.793 | 2,130 | |
| €0.797 | -0.027 | -3.3% | €0.808 | €0.815 | €0.794 | 13 | |
| €0.824 | +0.035 | +4.4% | €0.801 | €0.827 | €0.795 | 13 | |
| €0.789 | +0.011 | +1.4% | €0.773 | €0.791 | €0.772 | 214 | |
| €0.778 | +0.024 | +3.2% | €0.751 | €0.780 | €0.747 | 1,903 | |
| €0.754 | +0.001 | +0.1% | €0.740 | €0.765 | €0.740 | 16 | |
| €0.753 | -0.009 | -1.2% | €0.753 | €0.753 | €0.753 | 0 | |
| €0.762 | +0.012 | +1.6% | €0.748 | €0.767 | €0.744 | 0 | |
| €0.750 | +0.017 | +2.3% | €0.740 | €0.757 | €0.736 | 0 | |
| €0.733 | +0.001 | +0.1% | €0.734 | €0.734 | €0.733 | 11 | |
| €0.732 | +0.014 | +1.9% | €0.728 | €0.735 | €0.715 | 34 | |
| €0.718 | -0.052 | -6.8% | €0.762 | €0.769 | €0.715 | 8,504 | |
| €0.770 | +0.019 | +2.5% | €0.769 | €0.770 | €0.769 | 301 | |
| €0.751 | +0.015 | +2.0% | €0.751 | €0.751 | €0.751 | 12,518 | |
| €0.736 | -0.015 | -2.0% | €0.736 | €0.736 | €0.736 | 11,572 | |
| €0.751 | +0.004 | +0.5% | €0.746 | €0.754 | €0.745 | 9 | |
| €0.747 | +0.014 | +1.9% | €0.750 | €0.750 | €0.744 | 73 | |
| €0.733 | -0.003 | -0.4% | €0.734 | €0.739 | €0.733 | 6 | |
| €0.736 | +0.008 | +1.1% | €0.736 | €0.736 | €0.736 | 24,188 | |
| €0.728 | -0.013 | -1.8% | €0.726 | €0.735 | €0.724 | 20 | |
| €0.741 | 0.000 | 0.0% | €0.741 | €0.741 | €0.741 | 0 | |
| €0.741 | -0.005 | -0.7% | €0.741 | €0.741 | €0.741 | 23 | |
| €0.746 | +0.021 | +2.9% | €0.753 | €0.756 | €0.736 | 33 | |
| €0.725 | -0.054 | -6.9% | €0.757 | €0.759 | €0.723 | 31,720 | |
| €0.779 | -0.017 | -2.1% | €0.783 | €0.790 | €0.778 | 6,001 | |
| €0.796 | +0.010 | +1.3% | €0.796 | €0.796 | €0.796 | 0 | |
| €0.786 | +0.003 | +0.4% | €0.779 | €0.788 | €0.774 | 2 | |
| €0.783 | -0.060 | -7.1% | €0.785 | €0.785 | €0.781 | 1,067 | |
| €0.843 | -0.008 | -0.9% | €0.849 | €0.849 | €0.840 | 9,714 | |
| €0.851 | +0.008 | +0.9% | €0.851 | €0.851 | €0.851 | 6 | |
| €0.843 | -0.011 | -1.3% | €0.850 | €0.856 | €0.842 | 30 | |
| €0.854 | +0.012 | +1.4% | €0.853 | €0.854 | €0.853 | 1 | |
| €0.842 | +0.001 | +0.1% | €0.843 | €0.854 | €0.833 | 29 | |
| €0.841 | +0.030 | +3.7% | €0.833 | €0.854 | €0.821 | 5 | |
| €0.811 | +0.003 | +0.4% | €0.812 | €0.812 | €0.809 | 0 | |
| €0.808 | -0.017 | -2.1% | €0.808 | €0.808 | €0.808 | 0 | |
| €0.825 | -0.023 | -2.7% | €0.830 | €0.833 | €0.820 | 500 | |
| €0.848 | -0.004 | -0.5% | €0.865 | €0.867 | €0.839 | 14 | |
| €0.852 | -0.012 | -1.4% | €0.852 | €0.852 | €0.852 | 4 | |
| €0.864 | -0.046 | -5.1% | €0.903 | €0.916 | €0.861 | 1 | |
| €0.910 | -0.001 | -0.1% | €0.911 | €0.911 | €0.910 | 1 | |
| €0.911 | -0.014 | -1.5% | €0.911 | €0.911 | €0.909 | 4 | |
| €0.925 | -0.021 | -2.2% | €0.926 | €0.926 | €0.925 | 4,583 | |
| €0.946 | 0.000 | 0.0% | €0.947 | €0.951 | €0.945 | 4,108 | |
| €0.946 | -0.001 | -0.1% | €0.946 | €0.946 | €0.946 | 0 | |
| €0.947 | +0.012 | +1.3% | €0.947 | €0.947 | €0.947 | 500 | |
| €0.935 | -0.008 | -0.8% | €0.938 | €0.938 | €0.930 | 70 | |
| €0.943 | -0.029 | -3.0% | €0.975 | €0.976 | €0.933 | 21 | |
| €0.972 | -0.009 | -0.9% | €0.972 | €0.972 | €0.972 | 8,840 | |
| €0.981 | +0.020 | +2.1% | €0.987 | €0.992 | €0.980 | 0 |
- Ticker
- Frankfurt:940
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Jul 31, 2026
Rapport financier semestriel 2026
Latest deck · Apr 28, 2026
Shareholder Meeting (April 2026)
Shareholder meeting · 15 slides
Latest news
Rapport financier semestriel 2026
Jul 31, 2026
Closed €0.978 (+2.5%) on Aug 3, 2026
Availability of 2026 Half-year results financial report
Jul 31, 2026
Closed €0.978 (+2.5%) on Aug 3, 2026
EUROAPI_Mise à disposition du Rapport Financier Semestriel 2026
Jul 30, 2026
Closed €0.954 (+0.2%) on Jul 31, 2026
First-Half 2026 results confirm commercial and operational resilience in a challenging market environment - Transformation progressing as planned, including the divestment of the Brindisi site
Jul 28, 2026
Closed €1.21 (-2.3%) on Jul 29, 2026
Combined General Meeting of May 27, 2026
May 27, 2026
Closed €1.43 (+0.6%) on May 28, 2026
Assemblée Générale Mixte du 27 mai 2026
May 26, 2026
Closed €1.42 (-3.8%) on May 27, 2026
EUROAPI_Liquidity Contract
Apr 30, 2026
Closed €1.35 (-0.6%) on Apr 30, 2026
Availabilty of 2026 AGM preparatory documents
Apr 29, 2026
Closed €1.35 (-0.6%) on Apr 30, 2026
Availability of the 2025 Universal Registration Document, including the Annual Financial Report
Mar 27, 2026
Closed €1.24 (-0.9%) on Mar 30, 2026
2025 results: Core EBITDA margin improved despite sales headwinds, driven by strong cost discipline
Mar 3, 2026
Closed €1.33 (-26.7%) on Mar 4, 2026
Euroapi SA on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 12 in the last 12 months · 22 in all · newest Jul 31, 2026 · oldest 2025
- Decks
- 19 decks · latest Apr 28, 2026
Where Euroapi SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:EAPI · Home listing | Euronext | France | EUR |
| LSIN:0EAP | LSIN | United Kingdom | EUR |
| gettex:940 | gettex | Germany | EUR |
| LS Exchange:A3DJQ8 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3DJQ8 | Lang & Schwarz | Germany | EUR |
| Frankfurt:940 · This page | Frankfurt | Germany | EUR |
| Aquis:EAPIP | Aquis | United Kingdom | EUR |
| OTC:EAPIF | OTC | United States | USD |
| Tradegate:940 | Tradegate | Germany | EUR |
| Aquis:EAPIP | Aquis | United Kingdom | EUR |
| Dusseldorf:940 | Dusseldorf | Germany | EUR |
| Hamburg:940 | Hamburg | Germany | EUR |
| Munich:940 | Munich | Germany | EUR |
| Stuttgart:940 | Stuttgart | Germany | EUR |
| Turquoise:EAPIP | Turquoise | United Kingdom | EUR |
| Hanover:940 | Hanover | Germany | EUR |
| Xetra:940 | Xetra | Germany | EUR |
Valuation
EV/sales 0.4× against a median of 1.1×: the lowest of 11 Pharmaceuticals companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €312.6M EUR
- P/E
- Loss
- EV/sales
- 0.4×
- EV/EBITDA
- 31.6×
- Price/book
- 0.1×
- Gross margin
- 17.1%
- Operating margin
- −15.4%
- Net margin
- −24.9%
- Debt to equity
- 0.5×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Euroapi SA · EURONEXT:EAPI | US$67.31M | US$343.1M | n/a | 0.4× | 31.6× | 0.1× | −24.9% | 0.5× | n/a |
| Domesco Medical Import-Export JSC · HOSE:DMC | US$70.25M | US$47.49M | 9.1× | 0.6× | 5.1× | 1.1× | 9.6% | 0.0× | n/a |
| Zhengye Biotechnology Holding Limited · NASDAQ:ZYBT | US$70.14M | US$73.61M | n/a | 4.2× | n/a | 1.9× | −60.0% | 0.3× | 0.92 |
| OPTUS Pharmaceutical Co. Ltd. · KRX:131030 | US$68.82M | US$37.32M | 6.7× | 0.5× | 3.3× | 0.5× | 14.5% | 0.0× | n/a |
| Vetnostrum Animal Health Co., Ltd. · TWSE:6936 | US$68.48M | US$54.55M | 17.5× | 1.3× | 7.8× | 1.7× | 9.1% | 0.0× | n/a |
| TSH Biopharm Corp. Ltd. · TPEX:8432 | US$68.27M | US$35.76M | 16.2× | 0.9× | 4.8× | 1.6× | 10.4% | 0.0× | n/a |
| Wanbury Limited · NSE:WANBURY | US$67.68M | US$67.68M | 11.2× | 1.0× | 6.4× | 4.3× | 8.6% | 0.0× | n/a |
| Bangkok Lab and Cosmetic Public Company Limited · SET:BLC | US$66.78M | US$65.27M | 16.6× | 1.4× | 9.0× | 1.4× | 8.4% | 0.0× | n/a |
| JW Shinyak Corp. · KRX:067290 | US$66.62M | US$63.79M | 8.7× | 1.0× | 6.9× | 2.2× | 12.1% | 0.0× | n/a |
| Laboratorios Richmond SACIF Class B · BCBA:RICH | US$65.34M | US$173.1M | 8.4× | 2.1× | 7.5× | 0.9× | 9.3% | 1.5× | n/a |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A · TWSE:1762 | US$63.36M | US$76.28M | n/a | 2.7× | 51.1× | 0.7× | −5.5% | 0.2× | n/a |
| Median of the others | US$67.98M | US$64.53M | 10.2× | 1.1× | 6.9× | 1.5× | 9.2% | 0.0× | 0.92 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.00 EUR · Analysts' mean
- EPS, year to Dec 2026
- -0.95 · 2 analysts
- Revenue, year to Dec 2026
- 748.3M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Sophie Palliez-Capian | Investor Relations |
| Cécile Dussart | |
| Elizabeth Bastoni | |
| Emmanuel Blin | |
| Géraldine Leveau | |
| Jean-Yves Caminade | |
| Kevin Rodier | |
| Marie-Isabelle Penet | |
| Mattias Perjos | |
| Olivier Klaric | |
| Tristan Imbert |
Board
| Director |
|---|
| Cécile Dussart |
| Elizabeth Bastoni |
| Emmanuel Blin |
| Géraldine Leveau |
| Jean-Yves Caminade |
| Kevin Rodier |
| Marie-Isabelle Penet |
| Mattias Perjos |
| Olivier Klaric |
| Tristan Imbert |
Events
- Next results
- Mar 3, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Jul 29, 2025 · After close | −7.9% |
| Q4 2024 | Mar 31, 2025 | −3.0% |
| Q1 2023 | Apr 14, 2023 | +1.9% |
| Q2 2022 | Sep 1, 2022 · Before open | +3.6% |
| Q1 2022 | May 3, 2022 · Before open |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (April 2026) | Shareholder meeting | 15 slides | Apr 28, 2026 |
| FY2025 Earnings Presentation | Earnings | 33 slides | Mar 4, 2026 |
| Investor Presentation (September 2025) | Investor deck | 70 slides | Sep 9, 2025 |
| H1 2025 Earnings Presentation | Earnings | 21 slides | Jul 30, 2025 |
| Shareholder Meeting (May 2025) | Shareholder meeting | 60 slides | May 21, 2025 |
| FY2024 Earnings Presentation | Earnings | 34 slides | Mar 4, 2025 |
| Investor Presentation (October 2024) | Investor deck | 93 slides | Oct 11, 2024 |
| H1 2024 Earnings Presentation | Earnings | 26 slides | Jul 31, 2024 |
| Shareholder Meeting (May 2024) | Shareholder meeting | 48 slides | May 22, 2024 |
| Investor Presentation (May 2024) | Investor deck | 95 slides | May 2024 |
All 19 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2023 Earnings Presentation | Earnings | 53 slides | Feb 29, 2024 |
| Investor Presentation (2024) | Investor deck | 93 slides | 2024 |
| Investor Presentation (November 2023) | Investor deck | 95 slides | November 2023 |
| H1 2023 Earnings Presentation | Earnings | 32 slides | Aug 1, 2023 |
| Shareholder Meeting (May 2023) | Shareholder meeting | 50 slides | May 11, 2023 |
| FY2022 Earnings Presentation | Earnings | 30 slides | Mar 8, 2023 |
| Investor Presentation (2023) | Investor deck | 98 slides | 2023 |
| H1 2022 Earnings Presentation | Earnings | 29 slides | Sep 1, 2022 |
| Investor Day (April 2022) | Investor day | 102 slides | Apr 1, 2022 |
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 848.2M | 919.2M | 1.02B | 980.9M | 892.8M | 944.6M | 915.8M |
| Cost of revenue | 707.7M | 776.8M | 854.3M | 804.0M | 783.7M | 854.1M | 828.2M |
| Gross profit | 144.8M | 142.4M | 164.6M | 176.9M | 109.1M | 90.5M | 87.6M |
| Research and development | 27.3M | 25.8M | 29.6M | 21.8M | 17.0M | 19.9M | 16.3M |
| Selling, general and administrative | 80.3M | 89.4M | 90.0M | 90.5M | 55.4M | 42.7M | 39.3M |
| Operating income | -130.6M | -120.4M | -234.3M | -800.0K | 2.70M | -10.8M | -1.80M |
| Depreciation and amortization | 140.5M | 76.8M | 302.9M | 94.5M | 76.0M | 72.2M | 58.6M |
| EBITDA | 9.90M | -43.6M | 68.6M | 93.7M | 78.7M | 61.4M | 56.8M |
| Interest expense | 11.7M | 28.1M | 10.9M | 4.20M | 2.10M | 1.20M | 1.10M |
| Income before tax | -138.2M | -139.6M | -242.8M | 3.10M | -14.6M | -11.8M | -3.10M |
| Income tax | 72.9M | -9.00M | -53.0M | 18.2M | -6.50M | -5.50M | -5.60M |
| Net income | -211.2M | -130.6M | -189.7M | -15.0M | -8.10M | -6.30M | 2.50M |
| Earnings per share, basic | -2.23 | -1.38 | -2.02 | -0.16 | -0.09 | -0.07 | 0.03 |
| Earnings per share, diluted | -2.23 | -1.38 | -2.02 | -0.16 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 113.8M | 73.0M | 34.5M | 74.5M | 10.3M | 100.0K | -20.0M |
| Short-term investments | 5.70M | 6.20M | 8.40M | 4.80M | 19.0M | 153.8M | 133.0M |
| Receivables | 114.9M | 161.3M | 216.3M | 264.2M | 256.2M | 213.3M | 220.4M |
| Inventory | 495.2M | 524.2M | 644.8M | 594.7M | 569.5M | 584.1M | 596.9M |
| Current assets | 768.4M | 830.3M | 979.3M | 1.02B | 905.0M | 983.6M | 974.0M |
| Property, plant and equipment | 450.9M | 491.3M | 468.9M | 597.1M | 631.7M | 585.8M | 573.1M |
| Goodwill | 0 | 0 | 4.60M | 0 | |||
| Total assets | 1.30B | 1.49B | 1.61B | 1.74B | 1.62B | 1.60B | 1.58B |
| Accounts payable | 110.5M | 104.9M | 159.6M | 219.6M | 189.6M | 131.1M | 120.4M |
| Current liabilities | 295.1M | 311.2M | 508.9M | 456.5M | 387.7M | 365.3M | 312.5M |
| Total debt | 45.5M | 50.6M | 205.4M | 100.1M | 24.1M | 73.4M | 64.2M |
| Total liabilities | 516.7M | 506.0M | 684.7M | 625.9M | 607.0M | 611.6M | 558.6M |
| Shareholders' equity | 788.0M | 983.5M | 927.7M | 1.11B | 1.01B | 989.4M | 1.02B |
| Shares outstanding | 94.7M | 94.5M | 94.2M | 94.5M | 94.0M | 94.0M | 94.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 128.5M | 122.9M | 5.10M | 44.8M | 71.5M | 96.8M | 34.9M |
| Capital spending | -78.5M | -108.0M | -132.8M | -167.4M | -88.6M | -88.4M | -81.8M |
| Free cash flow | 47.0M | 14.9M | -127.7M | -122.6M | -17.1M | 8.40M | -46.9M |
| Cash from investing | -77.0M | -108.0M | -137.3M | -167.4M | -87.9M | -88.3M | -81.2M |
| Cash from financing | -13.3M | 26.5M | 92.2M | 187.8M | 26.5M | -8.40M | 46.2M |
| Dividends paid | 0 | 0 | 0 | 0 | -4.70M | -6.20M | |
| Share buybacks | 0 | -100.0K | -600.0K | -1.30M | 0 | 100.0K | -52.4M |
| Change in cash | 38.6M | 40.8M | -40.0M | 64.2M | 10.2M | 100.0K | -100.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EUROAPI_Mise à disposition du Rapport Financier Semestriel 2026 | Jul 30, 2026 | Other filings | Euronext |
| First-Half 2026 results confirm commercial and operational resilience in a challenging market environment - Transformation progressing as planned, including the divestment of the Brindisi site | Jul 28, 2026 | Acquisition or disposal | Euronext |
| Assemblée Générale Mixte du 27 mai 2026 | May 26, 2026 | Other filings | Euronext |
Cap table
Built by 6ix from Euroapi SA’s releases
- Common shares
- 95,528,648
- Fully diluted
- 95,528,648
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 95,528,648 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 95,528,648 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Cécile Dussart | Director · Since at least Nov 5, 2026 |
| Elizabeth Bastoni | Director · Since at least Nov 5, 2026 |
| Emmanuel Blin | Director · Since at least May 27, 2026 |
| Géraldine Leveau | Director · Since at least Nov 5, 2026 |
| Jean-Yves Caminade | Director · Since at least Nov 5, 2026 |
| Kevin Rodier | Director · Since at least Nov 5, 2026 |
| Marie-Isabelle Penet | Director · Since at least Nov 5, 2026 |
| Mattias Perjos | Director · Since at least Nov 5, 2026 |
| Olivier Klaric | Director · Since at least Nov 5, 2026 |
| Sophie Palliez-Capian | Investor Relations · Since at least Jul 31, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Tristan Imbert | Director · Since at least Dec 10, 2025 |
Log in to ask 6ix AI your own questions about Euroapi SA.